Article
Washington, D.C. - In a recent 10-week, three-dose phase II trial of inflaximab (Remicade), 87.9 percent of the 250 participants achieved PASI 75, while 58 percent achieved PASI 90 at the 10-week mark.
POLL: Are You Attending the 44th Annual Fall Clinical Dermatology Conference?
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Navigating Complexities and Unmet Needs of Chronic Hand Eczema
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Facing Challenges in Pediatric Plaque Psoriasis
Insights into the Association Between Pruritus and Liver Disease